Literature DB >> 295576

Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.

M Nesbit, R Chard, A Evans, M Karon, G D Hammond.   

Abstract

A study was done to evaluate intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. The results of this study demonstrate that the intramuscular method of administering L-asparaginase is as effective, but less toxic, than the intravenous method for children with advanced leukemia. The utilization of L-asparaginase in the initial induction of children with lymphoblastic and undifferentiated leukemia should be investigated. Its addition to the standard inducing agents may increase the percentage and ease of remission without significantly increasing toxicity.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 295576

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN： 0192-8562


  13 in total

1.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.

Authors:  S-H Chen; D Pei; W Yang; C Cheng; S Jeha; N J Cox; W E Evans; C-H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2010-06-30       Impact factor: 6.875

Review 4.  Hypersensitivity reactions from antineoplastic agents.

Authors:  R B Weiss; J R Baker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.

Authors:  Lesleigh S Abbott; Maria Zakova; Furqan Shaikh; Nisha Shewaramani; Angela Punnett; L Lee Dupuis
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

6.  Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.

Authors:  Rachel E Rau; ZoAnn Dreyer; Mi Rim Choi; Wei Liang; Roman Skowronski; Krishna P Allamneni; Meenakshi Devidas; Elizabeth A Raetz; Peter C Adamson; Susan M Blaney; Mignon L Loh; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2017-11-01       Impact factor: 3.167

Review 7.  L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Authors:  Rob Pieters; Stephen P Hunger; Joachim Boos; Carmelo Rizzari; Lewis Silverman; Andre Baruchel; Nicola Goekbuget; Martin Schrappe; Ching-Hon Pui
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

8.  Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.

Authors:  Susan L Kearney; Suzanne E Dahlberg; Donna E Levy; Stephan D Voss; Stephen E Sallan; Lewis B Silverman
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

Review 9.  Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group.

Authors:  Maura O'Leary; Mark Krailo; James R Anderson; Gregory H Reaman
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

10.  First-line treatment of acute lymphoblastic leukemia with pegasparaginase.

Authors:  Riccardo Masetti; Andrea Pession
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.